Polyglutamine (polyQ) diseases, including Huntington’s disease, are characterized by the progressive neuronal degeneration that results from the misfolding and aggregation of proteins that contain expanded repeats of uninterrupted glutamines. There is no cure for polyQ diseases, but increasing the concentration of protein chaperones might prevent some of the protein misfolding, and stop or slow the disease process. Neef et al. performed a pharmacological screen in yeast to identify molecules that increase the production of heat shock transcription factor 1 (HSF1), which regulates levels of protein chaperones in the cell. They identified HSF1A as a chemical activator of human HSF1 in yeast, which leads to Hsp70 expression in rat neurons. HSF1A treatment also reduced the aggregation of polyQ proteins in a Drosophila model of polyQ toxicity. This suggests that HSF1A may alleviate some of the misfolding and aggregation of polyQ proteins that causes neurodegeneration.
Neurodegeneration: proper folding of polyQ proteins
Neurodegeneration: proper folding of polyQ proteins. Dis Model Mech 8 March 2010; 3 (3-4): 122. doi:
Download citation file:
Advertisement
Cited by
Special Issue: The RAS Pathway

Our latest special issue is now complete. It showcases RAS-driven mechanisms of disease progression, and highlights approaches to treat and modify the disease course in model systems.
Call for papers: Moving Heart Failure to Heart Success

Disease Models & Mechanisms is pleased to welcome submissions for consideration for an upcoming special issue, Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy. Submission deadline: 4 July 2022.
Propose a new Workshop

Our Workshops bring together leading experts and early-career researchers from a range of scientific backgrounds. Applications are now open to propose Workshops for 2024, one of which will be held in a Global South country. .
A focus on Drosophila

In a series of front section articles, DMM is highlighting the versatility, breadth, and scope of Drosophila research in human disease modelling and translational medicine.
Apply for a DMM Conference Travel Grant

Aimed at early-career researchers wanting to attend in-person and virtual meetings, the next application deadline for a DMM Conference Travel Grant is 6 June 2022. Find out more and hear from past recipients about their experience of the grant.
Other journals from
The Company of Biologists